Trial Profile
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Pegfilgrastim Administered to Subjects With Newly Diagnosed, Locally-advanced or Metastatic Colorectal Cancer Treated With Bevacizumab & Either 5-fluorouracil, Oxaliplatin, Leucovorin (FOLFOX) or 5-fluorouracil, Irinotecan, Leucovorin (FOLFIRI)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 20 Dec 2021
Price :
$35
*
At a glance
- Drugs Pegfilgrastim (Primary)
- Indications Febrile neutropenia
- Focus Registrational; Therapeutic Use
- Acronyms PAVES
- Sponsors Amgen
- 16 Mar 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov
- 14 Aug 2014 Planned number of patients changed to 800.
- 14 Aug 2014 New trial record